Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: ZimbabweFázis nélkül

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV

A legfontosabb adatok

Hol
Harare (Zimbabwe)A helyszín megnézése

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 25-49 éves, HIV-vel élő nőket keres, akiknek HPV-alapú méhnyakrákszűrés esedékes. A klinikán belüli szűrést hasonlítja össze a klinikai és közösségi szűréssel.

Életkor
25-49 év, vagy a zimbabwei nemzeti szűrési irányelvek szerint
Nem
Csak nők
A betegség stádiuma
HIV-vel élő nők, akiket még soha nem szűrtek méhnyakrákra, vagy akiknek HPV-alapú vizsgálat vagy kontrollvizsgálat esedékes
Korábbi kezelés
Részt vehet, akit több mint 1 éve kezeltek méhnyakelváltozás miatt, és azóta nem volt szűrésen. Nem vehet részt, akit korábban invazív méhnyakrák miatt kezeltek.

A részvétel fő kizáró okai

  • Eltávolították a méhnyakát
  • Terhes, vagy a szüléstől számítva még nem telt el 6 hét
  • A legutóbbi szűrővizsgálata pozitív volt, és nem fejezte be a további ellátásra szóló beutalót
  • Korábban invazív méhnyakrák miatt kezelték

Ez a vizsgálat csak HIV-vel élő résztvevőket keres. A regiszter mondata, amelyen ez alapul: Are living with Human Immunodeficiency Virus (HIV)

Gépi kiolvasás: 2026. november 13.

Neked szólhat?

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 25 és 49 év között vagy?

Forrás: NCT07624123: ki vehet részt

Helyszínek itt: Zimbabwe

  • University of Zimbabwe Clinical Trials Research CentreHarare, ZimbabweContact: Bothwell T Guzha, MDNo longer taking part

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
UNC Lineberger Comprehensive Cancer Center
Azonosító
NCT07624123
A regiszteradat frissítve
2026. szeptember 2.
Eredeti leírás
This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.A teljes eredeti leírásKevesebb

Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial (CASCADE-3001-B)

This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.

The 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.

Further understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.

While it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers (CHWs) is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.

Bevonási feltételek: Are living with Human Immunodeficiency Virus (HIV); Are 25-49 years of age, or as recommended by the Zimbabwe National Screening Guidelines; Live in the catchment areas of or attend a study-eligible clinic; Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:; They have never undergone cervical cancer screening before, or; They have never undergone HPV-based testing before and are now due for Visual Inspection with Acetic Acid and Cervicography (VIAC), per national guidelines, or; They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and /or; They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia >1 year ago and have not had any follow-up cervical cancer screening since treatment.

Kizáró feltételek: Have previously been treated for invasive cervical cancer; Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral; Have had their cervix removed; Are pregnant or <6 weeks post-delivery.

Clinic Inclusion Criteria; Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH; These clinics should also have the ability to collect their own data; Such clinics could be supported by national programs and bilateral donor-funded initiatives.

ClinicalTrials.gov NCT07624123